Skip to content
Subscriber Only

Glaxo Malaria Vaccine Offers Less Protection to Infants

GlaxoSmithKline Plc’s experimental malaria vaccine was less effective in reducing illness in African infants than in older children in a study, suggesting further development will be necessary before wide distribution.

The shot, known as RTS,S, protected 31 percent of 6,537 children age six weeks to 12 weeks from developing symptoms over 12 months after receiving their third dose and it prevented 37 percent from suffering severe malaria, according to data from a late-stage study published today by the New England Journal of Medicine. That compares with 56 percent and 47 percent, respectively, in children age five months to 17 months, as reported by London-based Glaxo last year.